{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Altamira Therapeutics Ltd."},"Symbol":{"label":"Symbol","value":"CYTO"},"Address":{"label":"Address","value":"Bermuda"},"Phone":{"label":"Phone","value":"41 (0) 41 729 71 94"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Caribbean"},"CompanyDescription":{"label":"Company Description","value":"Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhore TM / SemaPhore TM delivery platforms). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets."},"CompanyUrl":{"label":"Company Url","value":"https://altamiratherapeutics.com/"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Covadonga Pañeda","title":"Chief Operating Officer"},{"name":"Samuel A. Wickline","title":"Chief Scientific Adviser"},{"name":"Thomas Meyer","title":"Chairman & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}